The Oncology Institute, Inc. TOI Clinical trials & other — Total Assets
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by The Oncology Institute, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about The Oncology Institute, Inc.'s clinical trials & other — total assets.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is The Oncology Institute, Inc.'s clinical trials & other — total assets?
- The Oncology Institute, Inc. (TOI) reported clinical trials & other — total assets of $6.04M in Q1 2026.
- How has The Oncology Institute, Inc.'s clinical trials & other — total assets changed year-over-year?
- The Oncology Institute, Inc.'s clinical trials & other — total assets decreased by 24.5% year-over-year, from $8M to $6.04M.
- What is the long-term trend for The Oncology Institute, Inc.'s clinical trials & other — total assets?
- Over 3 years (2022 to 2025), The Oncology Institute, Inc.'s clinical trials & other — total assets has grown at a -23.1% compound annual growth rate (CAGR), from $48.83M to $22.24M.
- What does clinical trials & other — total assets mean?
- This metric represents the total value of all resources, including property, equipment, and intangible assets, currently deployed within the clinical trials and other business segment. It serves as a measure of the capital intensity and scale of the segment's operations.